NCT00290277
Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years No drug interventions prevention 3 completed NCT00294047
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older prevention 3 completed NCT00426361
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects prevention 3 completed NCT01627561
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old prevention 3 completed NCT00316693
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine prevention 2 completed NCT01290393
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada No drug interventions Not Available Not Available terminated NCT00546078
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America prevention 2 completed NCT00947115
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects No drug interventions prevention 3 completed NCT01418937
Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study No drug interventions prevention 3 completed NCT00485732
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years prevention 3 completed NCT00344032
Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women prevention 3 completed NCT00549900
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females prevention 1 completed NCT01213459
Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia No drug interventions Not Available Not Available completed NCT01381575
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls prevention 3 completed NCT00541970
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs prevention 1 completed NCT01153906
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination No drug interventions Not Available Not Available completed NCT00518336
Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil prevention 2 completed NCT02100618
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study No drug interventions prevention 3 withdrawn NCT00689741
Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women prevention 2 completed NCT00586339
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females prevention 2 completed NCT02082639
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years prevention 3 withdrawn NCT00799825
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US prevention 3 completed NCT00996125
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects prevention 3 completed NCT01462357
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females prevention 3 completed NCT00929526
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study No drug interventions prevention 3 completed NCT00693966
Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females No drug interventions prevention 2 completed NCT00309166
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males. prevention 2 completed NCT00578227
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects prevention 3 completed NCT00250276
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. prevention 3 completed NCT01190176
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects prevention 3 completed NCT00169494
Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18 No drug interventions prevention 3 completed NCT00924794
Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Women With Recurrent Conizations in Norway No drug interventions Not Available Not Available terminated NCT01190189
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study prevention 3 completed NCT00492544
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age prevention 3 completed NCT01031069
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females prevention 4 completed NCT00423046
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age prevention 3 completed NCT00849381
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand No drug interventions prevention 3 completed NCT00122681
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 prevention 3 completed NCT00478621
Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A) prevention 1 completed NCT00552279
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age prevention 3 completed NCT00877877
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects. No drug interventions prevention 3 completed NCT00811798
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects. prevention 3 completed NCT00345878
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years prevention 3 completed NCT00456807
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years prevention 3 completed NCT00693615
Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females No drug interventions prevention 2 completed NCT00196937
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 prevention 3 completed NCT01101542
Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females Not Available Not Available completed NCT01277042
Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years) prevention 3 completed NCT01207999
Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer No drug interventions Not Available Not Available completed NCT00231413
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine. No drug interventions prevention 2 completed NCT00359619
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine No drug interventions prevention 2 completed NCT00306241
A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years No drug interventions prevention 3 completed NCT00369824
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects prevention 3 completed NCT00196924
Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18. No drug interventions prevention 3 completed NCT01953822
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom No drug interventions Not Available Not Available completed NCT00120848
Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults No drug interventions prevention 2 completed NCT00779766
Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects prevention 3 completed NCT01249365
The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study prevention 3 completed NCT01498627
Cervarix Long-term Safety Surveillance Not Available Not Available completed NCT01187927
Drug Use Investigation for Cervarix® Not Available Not Available completed NCT01905462
Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK Not Available Not Available completed NCT00637195
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299) prevention 3 completed NCT00937950
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects No drug interventions prevention 3 completed NCT00652938
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects prevention 3 completed NCT00534638
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents prevention 4 completed NCT04708041
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069) No drug interventions prevention 3 active_not_recruiting NCT05797246
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) treatment 2 recruiting NCT02858310
E7 TCR T Cells for Human Papillomavirus-Associated Cancers treatment 1 / 2 recruiting NCT01355003
GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077) No drug interventions Not Available Not Available terminated NCT04000503
Integrated Cervical Cancer Screening in Mayuge District Uganda (ASPIRE Mayuge) No drug interventions screening Not Available completed NCT00117884
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. No drug interventions treatment 2 terminated NCT06439433
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection No drug interventions treatment 2 completed NCT00461877
High-Risk HPV Infections in Women Aged 25 to 65 No drug interventions Not Available Not Available completed NCT00092547
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) prevention 3 completed NCT05450705
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071) No drug interventions prevention 3 active_not_recruiting NCT00194311
Human Papillomavirus (HPV) Infection in Pregnancy No drug interventions Not Available Not Available completed NCT00973856
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands No drug interventions treatment Not Available completed NCT03487549
Cantharidin and Occlusion in Verruca Epithelium treatment 2 completed NCT04015336
E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer No drug interventions treatment 2 terminated NCT04072913
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix No drug interventions basic_science Not Available completed NCT06371118
HPV Self-sampling for Women Who do Not Attend Cervical Cancer Screening Programme No drug interventions diagnostic Not Available recruiting NCT05580341
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 prevention 3 active_not_recruiting NCT00365716
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) No drug interventions prevention 2 completed NCT02631863
Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) No drug interventions treatment 2 completed NCT00312286
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. No drug interventions treatment 2 terminated NCT02845739
PApillomavirus in REnal Transplant Patient No drug interventions basic_science Not Available completed NCT03981822
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts treatment 2 completed NCT00496626
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED) prevention 3 completed NCT02346227
Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix treatment 3 completed NCT03903562
Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024) No drug interventions prevention 3 active_not_recruiting NCT04724980
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis treatment 1 / 2 active_not_recruiting NCT00365729
Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men No drug interventions Not Available Not Available unknown_status NCT00501189
Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities No drug interventions Not Available Not Available withdrawn NCT00743392
HPV Infections in Older Women No drug interventions Not Available Not Available completed NCT03929172
A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects No drug interventions prevention 1 completed NCT04044950
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer No drug interventions treatment 2 withdrawn NCT00549250
Human Papillomavirus 6/11 in the Lower Airway of Neonates No drug interventions Not Available Not Available completed NCT03584308
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal No drug interventions treatment 2 completed NCT01254643
A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). No drug interventions prevention 3 completed NCT01245764
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) prevention 3 completed NCT04115787
Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN No drug interventions Not Available Not Available unknown_status NCT03998254
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) prevention 3 active_not_recruiting NCT04124198
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma treatment Not Available recruiting NCT01101828
Self-collected Swabs for HPV Testing in 18-24 Year Old Women No drug interventions Not Available Not Available completed NCT01073293
A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007) No drug interventions prevention 3 completed NCT00124878
Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community No drug interventions prevention 3 unknown_status NCT03675256
The KEN SHE Study on HPV-vaccine Efficacy prevention 4 active_not_recruiting NCT02897232
Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination No drug interventions Not Available Not Available completed NCT03546842
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) prevention 3 completed NCT01295242
Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM) No drug interventions Not Available Not Available completed NCT06399341
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR). No drug interventions Not Available Not Available completed NCT04772534
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) prevention 3 completed NCT00421486
Oral Human Papillomavirus Infection in HIV-infected Men No drug interventions Not Available Not Available unknown_status NCT01894425
Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation No drug interventions Not Available Not Available completed NCT01709448
Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV No drug interventions Not Available Not Available unknown_status NCT05285826
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052) No drug interventions prevention 3 active_not_recruiting NCT04199689
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) prevention 3 active_not_recruiting NCT00188292
Screening for HIV-Associated Anal Cancer No drug interventions Not Available Not Available completed NCT03548740
Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection No drug interventions Not Available Not Available unknown_status NCT00380367
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) No drug interventions prevention 3 completed NCT02535104
Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV) treatment 1 / 2 completed NCT00685412
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 treatment 1 completed NCT04694495
HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study No drug interventions Not Available Not Available recruiting NCT05119855
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) prevention 3 completed NCT00157950
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) prevention 3 completed NCT04671823
Changes in the Prevalence of Oncogenic HPV Types No drug interventions Not Available Not Available unknown_status NCT04910438
Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo. No drug interventions Not Available Not Available recruiting NCT06538480
Confirmatory Study of PRGN-2012 in Patients with RRP treatment 3 recruiting NCT04864951
HPV Prevalence in Transpersons - a Prospective Study No drug interventions screening Not Available completed NCT05026047
Acceptability of Human Papillomavirus Self-sampling in Women Living With HIV No drug interventions prevention Not Available not_yet_recruiting NCT00316706
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine prevention 3 completed NCT05453006
HPV Self-Sampling in Somali Women No drug interventions screening Not Available active_not_recruiting NCT05592626
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT00090220
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) No drug interventions prevention 3 completed NCT05266898
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV prevention 4 recruiting NCT00828555
Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting No drug interventions Not Available Not Available completed NCT04459221
Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students prevention 4 completed NCT06416150
Reducing Urban Cervical Cancer Disparities No drug interventions screening Not Available not_yet_recruiting NCT05078554
HPV and Male Homosexuality in General Practice? No drug interventions Not Available Not Available completed NCT05916911
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR) No drug interventions treatment 4 recruiting NCT02114385
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020) prevention 3 completed NCT01030562
Immunogenicity of Off-Schedule Dosing of HPV Vaccine No drug interventions Not Available Not Available completed NCT06500767
Psycho-emotional Impact of Preoperative Counselling in Cervico-carcinoma Screening Programs No drug interventions Not Available Not Available recruiting